Delpha Capital Management’s Edwards Lifesciences EW Stock Holding History

Delpha Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-99	Closed	-$4K	–	466
2017 Q4	$4K	Buy	+99	New	+$3.63K	﹤0.01%	1339

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Delpha Capital Management's EW Position: Q1 2018 in Review

Delpha Capital Management sold out of Edwards Lifesciences (EW) in Q1 2018, closing a stake of 99 shares — an estimated $4K sold.

Delpha Capital Management first reported a position in EW in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 816 funds tracked by Wall St. Rank hold EW as of Q1 2018.

Delpha Capital Management reported no remaining Edwards Lifesciences position as of Q1 2018 after selling out during the quarter.
Delpha Capital Management sold 99 Edwards Lifesciences shares in Q1 2018, an estimated $4K.
Delpha Capital Management first reported a position in Edwards Lifesciences in Q4 2017 and held it in 1 quarter.
Delpha Capital Management's Edwards Lifesciences position peaked at $4K in Q4 2017.
816 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.